Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma Signs Collaborative Research Agreement with Stiefel Laboratories, Inc.

Abstract:
Starpharma today announced the signing of a collaborative research agreement with Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, to apply Starpharma's dendrimer nanotechnology to certain drugs used dermally. Stiefel Laboratories has five Global Research and Development Centers and has products marketed in more than 100 countries around the world.

Starpharma Signs Collaborative Research Agreement with Stiefel Laboratories, Inc.

MELBOURNE, Australia | Posted on December 3rd, 2007

The collaboration will apply Starpharma's dendrimer technology to deliver drugs through the skin with the aim of improving the effectiveness and tolerability of certain dermal treatments. Under the terms of the agreement Starpharma will receive staged payments on successful completion of technical milestones within the collaborative project. The agreement also deals with commercialization rights arising from the collaboration. Confidentiality provisions restrict disclosure of further details of the collaborative program and agreement.

"This agreement is significant for Starpharma in that it expands the applications for dendrimer technology to a new and potentially lucrative drug-delivery area. We consider drug delivery applications of dendrimers to represent a highly attractive commercial opportunity and we are delighted to be working with such a strong international partner in dermatology," commented Starpharma CEO, Dr. Jackie Fairley.

This is the fourth agreement signed by Starpharma this year to develop commercial applications for its dendrimer technology. Starpharma also has dendrimer drug delivery programs underway in cancer and protein therapeutics.

According to Gavin Corcoran, M.D., Senior Vice President, Global Research & Development for Stiefel Laboratories, this development agreement is aligned with Stiefel's commitment to advancing the field of dermatology.

"Our partnership with Starpharma and the resulting agreement will add to Stiefel's innovative technology offerings including the VersaFoam(TM), EPX(TM) and dimethylisosorbide (DMI) vehicles that have greatly enhanced topical drug delivery," said Corcoran.

In February 2007 Starpharma entered into a worldwide exclusive license and supply agreement with EMD Biosciences, part of Merck KGaA's Performance and Life Science Chemicals division. Under the terms of that agreement, Starpharma supplies EMD with Priofect(R) transfection reagents based on Priostar(R) proprietary dendrimers for the DNA and siRNA transfection research markets. Additionally two co-development agreements have recently been signed in relation to condom coating applications of Starpharma's lead product VivaGel(R). One of the agreements is with SSL International Plc, the makers of Durex(R), and a second with an undisclosed condom manufacturer. VivaGel(R) is a vaginal microbicide being developed under IND to prevent the transmission of HIV and genital herpes during sexual intercourse.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX: SPL; Pink Sheets: SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) (clindamycin, 1% - benzoyl peroxide, 5%) Topical Gel; Evoclin(R) (clindamycin phosphate, 1%) Foam; Luxiq(R) (betamethasone valerate, 0.12%) Foam; MimyX(R); Olux(TM) (clobetasol propionate, 0.05%) Foam; Olux-E(TM) (clobetasol propionate, 0.05%) Foam; Soriatane(R) (acitretin) CK CONVENIENCE KIT(TM); Verdeso(TM) (desonide, 0.05%) Foam; Brevoxyl(R) (benzoyl peroxide, 4% or 8%) Creamy Wash packaged in the convenient new BREVOXYL Acne Wash Kit; Extina(R) (ketoconazole, 2%) Foam; Oilatum(R); Physiogel(R); Stieprox(R) (ciclopirox olamine); REVALESKIN(TM); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit http://www.stiefel.com/ .

For more information, please click here

Contacts:
Media
Rebecca Wilson
Buchan Consulting
Tel: +61 2 9237 2800
Mob: +61 417 382 391


Philippa Harris
Buchan Consulting
Tel: +61 2 9237 2811
Mob: +61 408 465 800


Starpharma
http://www.starpharma.com/

Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Alliances/Partnerships/Distributorships

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014

New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

Research partnerships

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE